Cerevel Therapeutics Holdings, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2020 to Q1 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Cerevel Therapeutics Holdings, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2020 to Q1 2024.
  • Cerevel Therapeutics Holdings, Inc. Net Income (Loss) Attributable to Parent for the quarter ending March 31, 2024 was -$132M, a 26.5% decline year-over-year.
  • Cerevel Therapeutics Holdings, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending March 31, 2024 was -$460M, a 18.8% decline year-over-year.
  • Cerevel Therapeutics Holdings, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$433M, a 23.1% decline from 2022.
  • Cerevel Therapeutics Holdings, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$352M, a 56% decline from 2021.
  • Cerevel Therapeutics Holdings, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$225M, a 48.1% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 -$460M -$132M -$27.6M -26.5% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 -$433M -$133M -$39.9M -42.9% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-27
Q3 2023 -$393M -$96.4M +$3.58M +3.58% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-01
Q2 2023 -$397M -$99.5M -$9.06M -10% Apr 1, 2023 Jun 30, 2023 10-Q 2023-11-01
Q1 2023 -$388M -$104M -$36M -52.7% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 -$352M -$92.8M -$33.8M -57.2% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-27
Q3 2022 -$318M -$99.9M -$37.9M -61% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-01
Q2 2022 -$280M -$90.5M -$37.2M -69.9% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-01
Q1 2022 -$243M -$68.3M -$17.3M -34% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-01
Q4 2021 -$225M -$59.1M -$25.9M -78% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-27
Q3 2021 -$199M -$62.1M -$23M -59% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 -$176M -$53.2M -$26.5M -99.3% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-08
Q1 2021 -$150M -$51M +$2.23M +4.19% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-08
Q4 2020 -$152M -$33.2M Oct 1, 2020 Dec 31, 2020 10-K 2023-02-22
Q3 2020 -$39M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 -$26.7M Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-10
Q1 2020 -$53.2M Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.